

# Leaders in the Biosimilar Sector- Sandoz, Oncobiologics, Merck, Samsung Bioepis- will meet at Biosimilars&Biobetters USA

*Industry Leaders will meet at Biosimilars & Biobetters USA 2015– the must-attend premier industry event which will take place in Iselin this November*

ISELIN, NEW JERSEY, USA, August 4, 2015 /EINPresswire.com/ -- In recent weeks, the industry has been thriving with news about Biosimilars and Biobetters with a court allowing Sandoz to launch the first US biosimilar in September, Oncobiologics to raise \$31M for a Phase III biosimilar play against Humira, and Merck and Samsung's Humira biosimilar to come through in Phase III.

With all of this happening, SMi Group is excited to announce that John Pakulski, Head US Biopharmaceutical Regulatory Affairs, Sandoz, will be giving a spotlight presentation on "The First Biosimilar Approved by the FDA." Oncobiologics will be the co-host of the post-conference workshop on "Development, Regulatory & Commercial Needs for Global Biosimilars", while Merck and Samsung Bioepis confirming their attendance.

The [Biosimilars and Biobetters USA 2015](http://www.biosimilars-usa.com/evvnt), taking place in Iselin, USA, on the 16th and 17th of November, will enable attendees to understand the latest B&B markets, from rebranding to regulatory landscape. Over 80 industry experts from the world's leading pharmaceutical and biotech companies will meet in New Jersey to discuss the current challenges and solutions to accelerate commercialization. Through practical case studies and workshops, attendees will gain a 360° overview of the global B&B market to ensure ROI for investments. For more information on the event visit [www.biosimilars-usa.com/einpr](http://www.biosimilars-usa.com/einpr)

“

The Biosimilars and Biobetters USA 2015 will enable attendees to understand the latest B&B markets, from rebranding to regulatory landscape.”

*SMi Group*

will:



Through attending Biosimilars and Biobetters USA 2015, you

- Hear the latest on the evolving regulatory biosimilar landscape and review the guidelines
- Gain understanding of strategies for market access and commercialization of products
- Learn about global biosimilar market developments, in particular the lucrative opportunities in emerging markets

In addition to the conference, the event will feature [two post-conference workshops](#):

- “A Regulatory Perspective on Biosimilars” (led by Ravi S. Harapanhalli, Vice President, ParExel and former Senior Executive, FDA) and
- “Development, Regulatory & Commercial Needs for Global Biosimilars” (led by Gerry McGettigan, CEO & Regulatory Expert and Graeme Deuchar, Product Development Expert from Kinesys Consulting Ltd, and Liz Yamashita, VP, Regulatory & Clinical Affairs, Oncobiologics)

Expert speakers 2015 also include senior representatives from ParExel, Merck, Formycon AG, Dr. Reddy's Laboratories, Inc, AGES Regulatory Agency, Janssen Research and Development, LLC, IMS Health, Norwegian Medicines Agency and many more. For more information on the speakers 2015 visit [www.biosimilars-usa.com/einpr](http://www.biosimilars-usa.com/einpr)

Biosimilars and Biobetters USA 2015 is proudly sponsored by Schwegman Lundberg & Woessner.

Early bird places are strictly limited. To take advantage of this, please register today at [www.biosimilars-usa.com/einpr](http://www.biosimilars-usa.com/einpr)

----- END -----

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Julia Rotar  
SMi Group Ltd  
+44 (0) 207 827 6088  
email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.